STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

MNKD MANNKIND CORPORATION StockScouter® Report

5

StockScouter® Score

MANNKIND CORPORATION, a small cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with slightly less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
  • One or more analysts has significantly increased quarterly earnings estimates for MNKD. Positive

 

Concerns

  • Two or more executives, directors or major shareholders sold a large number of shares recently. Very negative
  • The enterprise value-to-sales ratio is higher than the average for comparably-sized companies in the StockScouter universe. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 40% done.
Progress: 60% done.
Low
High

Core Model Grades

B
F
D
C

Previous Ratings

7
7
3